Role of the endocannabinoid system in obesity induced by neuropeptide y overexpression in noradrenergic neurons

Nutrition and Diabetes

Volumn 5, Issue , 2015, Pages

  Vahatalo L H ^a   Ruohonen, S T ^a   Makela S ^a   Ailanen, L ^a   Penttinen, A M ^a   Stormi, T ^a   Kauko, T ^a   Piscitelli, F ^b   Silvestri, C ^b   Savontaus, E ^a,c   Di Marzo, V ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b CNR   (Italy)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID; NEUROPEPTIDE Y;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; FAT MASS; FOOD INTAKE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HYPOTHALAMUS; IMPAIRED GLUCOSE TOLERANCE; LIVER; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; NORADRENERGIC NERVE CELL; OBESITY; PANCREAS; PHENOTYPE; PRIORITY JOURNAL; SOLEUS MUSCLE; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

EID: 84928748528     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2015.1     Document Type: Article

References (44)

1. Silvestri C, Di Marzo V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 2012; 21: 1309-1322.
2. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
3. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013; 17: 475-490.
4. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 2009; 158: 451-461.
5. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
6. Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic antiinflammatory switch. Eur J Pharmacol 2008; 583: 322-339.
7. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004; 143: 520-523.
8. Engeli S. Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 2008; 20: 110-115.
9. Bisogno T, Mahadevan A, Coccurello R, Chang JW, Allara M, Chen Y et al. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br J Pharmacol 2013; 169: 784-793.
10. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713.
11. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-1758.
12. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986; 7: 1189-1192.
13. Yeung EH, Zhang C, Chen J, Bowers K, Hu FB, Kang G et al. Polymorphisms in the neuropeptide Y gene and the risk of obesity: findings from two prospective cohorts. J Clin Endocrinol Metab 2011; 96: E2055-E2062.
14. Pesonen U. NPY L7P polymorphism and metabolic diseases. Regul Pept 2008; 149: 51-55.
15. Shi YC, Lin S, Castillo L, Aljanova A, Enriquez RF, Nguyen AD et al. Peripheralspecific y2 receptor knockdown protects mice from high-fat diet-induced obesity. Obesity 2011; 19: 2137-2148.
16. Zhang L, Macia L, Turner N, Enriquez RF, Riepler SJ, Nguyen AD et al. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int J Obes 2010; 34: 357-373.
17. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13: 803-811.
18. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 1984; 8: 225-235.
19. Ruohonen ST, Pesonen U, Moritz N, Kaipio K, Röyttä M, Koulu M et al. Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance. Diabetes 2008; 57: 1517-1525.
20. Vähätalo LH, Ruohonen ST, Mäkelä S, Kovalainen M, Huotari A, Mäkelä KA et al. Neuropeptide Y in the noradrenergic neurons induces obesity and inhibits sympathetic tone in mice. Acta Physiol (Oxf) 2015; 213: 902-919.
21. Toukola L, Ruohonen S, Röyttä M, Kilpeläinen M, Huotari A, Herzig K et al. Poster Session 2 Cell and Molecular Biology: Obesity in mice overexpressing neuropeptide Y in noradrenergic neurons. Obesity 2009; 17: S167-S241 (abstract 453).
22. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005; 49: 646-652.
23. Zhang L, Lee NJ, Nguyen AD, Enriquez RF, Riepler SJ, Stehrer B et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab 2010; 12: 591-603.
24. Poncelet M, Maruani J, Calassi R, Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003; 343: 216-218.
25. Ruohonen ST, Vähätalo LH, Savontaus E. Diet-induced obesity in mice overexpressing neuropeptide y in noradrenergic neurons. Int J Pept 2012; 2012: 452524.
26. Ruohonen ST, Savontaus E, Rinne P, Rosmaninho-Salgado J, Cavadas C, Ruskoaho H et al. Stress-induced hypertension and increased sympathetic activity in mice overexpressing neuropeptide Y in noradrenergic neurons. Neuroendocrinology 2009; 89: 351-360.
27. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A et al. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 2003; 139: 1005-1013.
28. Bartelt A, Orlando P, Mele C, Ligresti A, Toedter K, Scheja L et al. Altered endocannabinoid signalling after a high-fat diet in Apoe(-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance. Diabetologia 2011; 54: 2900-2910.
29. Li L, Bender KJ, Drew PJ, Jadhav SP, Sylwestrak E, Feldman DE. Endocannabinoid signaling is required for development and critical period plasticity of the whisker map in somatosensory cortex. Neuron 2009; 64: 537-549.
30. Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG et al. The cannabinoid Delta(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes 2013; 3: e68.
31. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003; 462: 125-132.
32. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180.
33. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008; 57: 1262-1268.
34. Judge MK, Zhang Y, Scarpace PJ. Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding. J Endocrinol 2009; 203: 281-290.
35. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 2008; 29: 229-233.
36. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008; 11: 152-159.
37. Di Marzo V, Cristino L. Why endocannabinoids are not all alike. Nat Neurosci 2008; 11: 124-126.
38. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008; 149: 2557-2566.
39. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes 2005; 29: 183-187.
40. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006; 55: 3403-3410.
41. O'Hare JD, Zielinski E, Cheng B, Scherer T, Buettner C. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 2011; 60: 1055-1062.
42. Malenczyk K, Jazurek M, Keimpema E, Silvestri C, Janikiewicz J, Mackie K et al. CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release. J Biol Chem 2013; 288: 32685-32699.
43. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
44. Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012; 142: 1218-1228.